Arcapta FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2021.
FDA Approved: Yes (Discontinued) (First approved July 1, 2011)
Brand name: Arcapta
Generic name: indacaterol
Dosage form: Neohaler
Previous Name: QAB149
Company: Novartis Pharmaceuticals Corp.
Treatment for: COPD
Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Development timeline for Arcapta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.